Can-Fite BioPharma Files Routine 6-K Report
Ticker: CANF · Form: 6-K · Filed: Mar 18, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Mar 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, compliance
TL;DR
Can-Fite BioPharma filed a 6-K, mostly referencing old stuff into active filings. No new news.
AI Summary
On March 18, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8 and Form F-3. This filing is a routine report for a foreign private issuer and does not appear to contain new financial or operational disclosures beyond the incorporation by reference.
Why It Matters
This filing indicates ongoing compliance with SEC reporting requirements for foreign private issuers. It incorporates previous disclosures into active registration statements, which can be relevant for investors tracking the company's filings.
Risk Assessment
Risk Level: low — The filing is a routine report of a foreign private issuer and does not appear to contain new material information or significant changes.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Filer of the 6-K report
- 26 Ben Gurion Street Ramat Gan 5257346 Israel (location) — Principal executive offices address
- March 18, 2025 (date) — Date of filing and report
FAQ
What is the purpose of this Form 6-K filing by Can-Fite BioPharma Ltd.?
The purpose of this Form 6-K filing is to report information required by a foreign private issuer, specifically incorporating by reference a press release into the registrant's existing Registration Statements on Form S-8 and Form F-3.
When was this Form 6-K filed?
This Form 6-K was filed on March 18, 2025.
Which registration statements are being updated by this filing?
This filing incorporates information into Can-Fite BioPharma Ltd.'s Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000, and 333-281872).
Is Can-Fite BioPharma Ltd. required to file annual reports under Form 20-F or Form 40-F?
Can-Fite BioPharma Ltd. indicates it files annual reports under Form 20-F.
What is the principal executive office address for Can-Fite BioPharma Ltd.?
The principal executive offices are located at 26 Ben Gurion Street, Ramat Gan, 5257346, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 18, 2025 regarding Can-Fite BioPharma Ltd. (CANF).